Umifenovir . HCl [Arbidol]
| Code | Size | Price |
|---|
| AG-CR1-3718-M010 | 10 mg | £60.00 |
Quantity:
| AG-CR1-3718-M050 | 50 mg | £150.00 |
Quantity:
| AG-CR1-3718-M250 | 250 mg | £430.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
Ambient
Storage:
-20°C
Documents
Further Information
Alternate Names/Synonyms:
Arbidol; ARB
Appearance:
White to off-white solid.
CAS:
131707-23-8
EClass:
32160000
Form (Short):
liquid
GHS Symbol:
GHS07
Handling Advice:
Keep cool and dry.
Hazards:
H315, H319
InChi:
S/C22H25BrN2O3S.ClH/c1-5-28-22(27)20-18(13-29-14-9-7-6-8-10-14)25(4)17-11-16(23)21(26)15(19(17)20)12-24(2)3;/h6-11,26H,5,12-13H2,1-4H3;1H
InChiKey:
OMZHXQXQJGCSKN-UHFFFAOYSA-N
Long Description:
Chemical. CAS: 131707-23-8. Formula: C22H25BrN2O3S . HCl. MW: 477.4 . 36.5. Umifenovir is a broad-spectrum, indole-based antiviral compound that blocks viral fusion with target membranes, prohibiting viral entry into cells. Fusion between the viral envelope (surrounding the viral capsid) and the cell membrane of the target cell is inhibited. This prevents viral entry to the target cell and therefore protects it from infection. Umifenovir targets a common critical step for viral replication and therefore it is effective against numerous viruses, including influenza A, B and C and hepatitis B and C. Recent studies indicate that umifenovir also has in vitro effectiveness at preventing entry of Zika virus, Ebola virus, Tacaribe arenavirus and human herpes virus 8 in mammalian cell cultures. Clinical studies against SARS-CoV-2 are ongoing to test its efficacy and safety in the treatment of coronavirus disease 2019 (COVID-19). Besides its antiviral action, it has been reported to produce an immunomodulatory response by inducing interferon production and stimulating the phagocytic function of macrophages. It also displays anti-inflammatory activity.
MDL:
MFCD00344795
Molecular Formula:
C22H25BrN2O3S . HCl
Molecular Weight:
477.4 . 36.5
Package Type:
Vial
Precautions:
P302+P352, P305+351+338
Product Description:
Umifenovir is a broad-spectrum, indole-based antiviral compound that blocks viral fusion with target membranes, prohibiting viral entry into cells. Fusion between the viral envelope (surrounding the viral capsid) and the cell membrane of the target cell is inhibited. This prevents viral entry to the target cell and therefore protects it from infection. Umifenovir targets a common critical step for viral replication and therefore it is effective against numerous viruses, including influenza A, B and C and hepatitis B and C. Recent studies indicate that umifenovir also has in vitro effectiveness at preventing entry of Zika virus, Ebola virus, Tacaribe arenavirus and human herpes virus 8 in mammalian cell cultures. Clinical studies against SARS-CoV-2 are ongoing to test its efficacy and safety in the treatment of coronavirus disease 2019 (COVID-19). Besides its antiviral action, it has been reported to produce an immunomodulatory response by inducing interferon production and stimulating the phagocytic function of macrophages. It also displays anti-inflammatory activity.
Purity:
>98% (HPLC)
Signal word:
Warning
SMILES:
BrC1=C(O)C(CN(C)C)=C(C(C(OCC)=O)=C(CSC2=CC=CC=C2)N3C)C3=C1.Cl
Solubility Chemicals:
Soluble in ethanol (10mg/ml), DMSO (15mg/ml) or DMF (20mg/ml).
Transportation:
Non-hazardous
UNSPSC Category:
Biochemical Reagents
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 2 years after receipt when stored at -20°C.
References
Arbidol: a broad-spectrum antiviral that inhibits acute and chronic HCV infection: Y.S. Boriskin, et al.; Virol. J. 3, 56 (2006) | Biochemical mechanism of hepatitis C virus inhibition by the broad-spectrum antiviral arbidol: E.I. Pecheur, et al.; Biochemistry 46, 6050 (2007) | Antiviral activity of arbidol against influenza A virus, respiratory syncytial virus, rhinovirus, coxsackie virus and adenovirus in vitro and in vivo: L. Shi, et al.; Arch. Virol. 152, 1447 (2007) | Arbidol: A broad-spectrum antiviral compound that blocks viral fusion: Y.S. Boriskin, et al.; Curr. Med. Chem. 15, 997 (2008) (Review) | Antiviral activity of Arbidol against Coxsackie virus B5 in vitro and in vivo: Q. Zhong, et al.; Arch. Virol. 154, 601 (2009) | Membranotropic effects of arbidol, a broad anti-viral molecule, on phospholipid model membranes: J. Villalain; J. Phys. Chem. B 114, 8544 (2010) | Targeting cell entry of enveloped viruses as an antiviral strategy: E. Teissier, et al.; Molecules 16, 221 (2010) (Review) | Mechanism of inhibition of enveloped virus membrane fusion by the antiviral drug arbidol: E. Teissier, et al.; PLoS One 6, e15874 (2011) | Antiviral and anti-inflammatory activity of arbidol hydrochloride in influenza A (H1N1) virus infection: Q. Liu, et al.; Acta Pharmacol. Sin. 34, 1075 (2013) | Arbidol inhibits viral entry by interfering with clathrin-dependent trafficking: J. Blaising, et al.; Antiviral Res. 100, 215 (2013) | Arbidol as a broad-spectrum antiviral: an update: J. Blaising, et al.; Antiviral Res. 107, 84 (2014) (Review) | The Synthetic Antiviral Drug Arbidol Inhibits Globally Prevalent Pathogenic Viruses: E.I. Pecheur, et al.; J. Virol. 90, 3086 (2016) | Antiviral activity of arbidol hydrochloride against herpes simplex virus I in vitro and in vivo: M.K. Li, et al.; Int. J. Antimicrob. Agents 51, 98 (2018) | The Antiviral Drug Arbidol Inhibits Zika Virus: S.L. Fink, et al.; Sci. Rep. 8, 8989 (2018) | Arbidol (Umifenovir): A Broad-Spectrum Antiviral Drug That Inhibits Medically Important Arthropod-Borne Flaviviruses: J. Haviernik, et al.; Viruses 10, E184 (2018) | Arbidol and Other Low-Molecular-Weight Drugs That Inhibit Lassa and Ebola Viruses: C.E. Hulseberg, et al.; J. Virol. 93, e02185 (2019) | Discovering drugs to treat coronavirus disease 2019 (COVID-19): L. Dong, et al.; Drug Discov. Ther. 14, 58 (2020)